Want to see FDMT full AI Analyst Report?
Top Page
4D Molecular Therapeutics
(NASDAQ:FDMT)
Select Model
Select Model
Rating:50Neutral
Price Target:
$11.00
▼(-26.22% Downside)
Action:Reiterated
Date:10/24/26
The score is primarily held back by weak financial performance—large ongoing losses and heavy cash burn—despite a low-leverage balance sheet and improving revenue. Technical indicators also point to continued negative momentum. Valuation is difficult to assess due to negative earnings, while the recent Phase 3 start and supportive clinical data provide a meaningful (but risk-dependent) positive offset.
Positive Factors
Revenue Growth
The sharp increase in revenue indicates meaningful commercial or partnership-related progress from a low base. If sustained, a larger revenue stream can improve operating leverage, support development investment, and strengthen the company’s ability to advance its gene-therapy pipeline.
Negative Factors
Persistent Losses
FDMT remains far from breakeven despite improved revenue, so future operating performance still depends on successful clinical and commercial execution. Large recurring losses can erode the capital base, limit financial flexibility, and make eventual profitability dependent on substantial pipeline progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp increase in revenue indicates meaningful commercial or partnership-related progress from a low base. If sustained, a larger revenue stream can improve operating leverage, support development investment, and strengthen the company’s ability to advance its gene-therapy pipeline.
Read all positive factors
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$596.64M
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth278712.12%
EPS Growth26.59%
CountryUS
Employees196
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.72
Shares Outstanding55,244,210
10 Day Avg. Volume986,569
30 Day Avg. Volume1,060,681
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue6.66
Enterprise Value/Gross Profit15.85
Enterprise Value/Ebitda-3.33
Forecast
1Y Price Target
$30.57Price Target Upside105.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$13.26M
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a ...
4D Molecular Therapeutics Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
70
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.01M | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | 38.65M | 77.58M | -141.26M | -76.37M | -77.12M | -43.32M |
| EBITDA | -183.96M | -132.48M | -154.16M | -95.09M | -103.61M | -68.30M |
| Net Income | -179.18M | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 492.62M | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 361.33M | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 39.22M | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 84.96M | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 407.66M | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | ||||||
| Free Cash Flow | -156.67M | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -156.07M | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -16.64M | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 165.92M | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Negative
14.91
Price Trends
13.99
Negative
12.40
Negative
10.76
Positive
Market Momentum
-0.57
Positive
33.15
Neutral
15.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Negative. The current price of 14.91 is above the 20-day moving average (MA) of 12.91, above the 50-day MA of 13.99, and above the 200-day MA of 10.76, indicating a neutral trend. The MACD of -0.57 indicates Positive momentum. The RSI at 33.15 is Neutral, neither overbought nor oversold. The STOCH value of 15.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
4D Molecular Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $653.34M | -3.54 | -73.18% | ― | ― | 9.05% | |
52 Neutral | $640.84M | -8.68 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $596.64M | -3.97 | -41.33% | ― | 278712.12% | 26.59% | |
50 Neutral | $403.95M | 36.07 | -0.02% | ― | 125.12% | 98.69% | |
48 Neutral | $241.32M | -3.59 | -27.15% | ― | ― | 45.56% | |
45 Neutral | $176.41M | -1.20 | -114.26% | ― | -62.08% | -2.62% |
* Healthcare Sector Average
FDMT
4D Molecular Therapeutics
10.80
-1.47
-11.98%
ASMB
Assembly Biosciences
19.84
-9.96
-33.42%
KRRO
Korro Bio
11.98
-27.60
-69.73%
DSGN
Design Therapeutics
10.24
3.27
46.92%
IMRX
Immuneering
3.73
-2.57
-40.79%
AURA
Aura Biosciences Inc
6.30
0.20
3.28%
4D Molecular Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial
Positive
Sep 28, 2026
On September 28, 2026, 4D Molecular Therapeutics reported that it has enrolled the first patients across multiple global sites in 4SIGHT, a Phase 3 randomized, double-masked trial of intravitreal gene therapy 4D-150 versus aflibercept in treatment...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.